Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Prostate Cancer
Would you offer modest hypofractionation (e.g. 70 Gy/28 fractions) to a patient with intermediate risk prostate cancer and celiac disease?
Answer from: Radiation Oncologist at Community Practice
Celiac disease is primary small bowel disease. RT effect on rectum would not be exaggerated from the disease.
Sign in or Register to read more
5901
Related Questions
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
In asymptomatic patients with castrate resistant prostate cancer who have failed chemotherapy and have progressive vertebral body metastases, when do you prescribe lutetium-177 vs prophylactic spinal radiation?
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
Would you consider re-irradiation for a prostate local failure for a patient who initially received standard fractionation with a focal SIB to 95 Gy, or a SBRT boost with cyberknife after EBRT?
What are your top takeaways from ASCO GU 2025?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
Is there any evidence that ivermectin suppresses the PSA level in prostate cancer?
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?
How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?